Skip to main content
    L

    Longeveron LLC (LGVN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.14
    -0.35 (-14.06%)

    Market Cap: $8.40M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Longeveron LLC (LGVN) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Longeveron LLC reported EPS of -$1.91, below the -$1.70 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    30%(6/20)
    Avg Surprise
    -9.02%

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus-$1.73
    RangeN/A
    4 analysts
    Revenue Consensus
    $1.62M
    Range$1.56M - $1.67M
    4 analysts

    Next Report

    LGVN's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    LGVN Earnings Call

    The latest LGVN earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    Earnings History

    Of the 20 quarters below that had an estimate, LGVN beat 6, missed 13 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $115000, down 16.1% from $137000 a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$1.91-$1.70-$1.70 - -$1.70-12.35%MissN/A1N/ANov 12, 2026$115000
    Jun 30, 2026-$0.19-$0.19-$0.21 - -$0.180.00%In lineN/A3N/AAug 12, 2026$287000
    Mar 31, 2026-$0.19-$0.17-$0.23 - -$0.12-11.76%MissN/A41 up, 0 downMay 13, 2026$398000
    Dec 31, 2025-$2.20-$3.67N/A+40.00%BeatN/A32 up, 1 downMar 17, 2026$365000
    Sep 30, 2025-$0.39-$0.26-$0.26 - -$0.25-50.00%MissN/A32 up, 1 downNov 4, 2025$137000
    Jun 30, 2025-$0.33-$0.35N/A+5.71%BeatN/AN/A0 up, 0 downAug 13, 2025$316000
    Mar 31, 2025-$0.34-$0.33N/A-3.03%MissN/AN/A0 up, 0 downMay 8, 2025$381000
    Dec 31, 2024-$0.27-$0.20N/A-35.00%MissN/AN/A0 up, 0 downFeb 28, 2025$603000
    Sep 30, 2024-$0.34-$0.44-$0.55 - -$0.27+22.73%BeatN/A30 up, 0 downNov 12, 2024$773000
    Jun 30, 2024-$1.83-$0.87-$1.12 - -$0.62-110.34%MissN/A22 up, 0 downAug 14, 2024$468000
    Mar 31, 2024-$1.61-$2.00-$2.70 - -$1.31+19.50%BeatN/A21 up, 0 downMay 14, 2024$548000
    Dec 31, 2023-$2.50-$2.05-$2.30 - -$1.90-21.95%MissN/A20 up, 0 downFeb 27, 2024$63000
    Sep 30, 2023-$2.80-$2.40-$2.40 - -$2.10-16.67%MissN/A20 up, 0 downNov 10, 2023$150000
    Jun 30, 2023-$2.70-$2.47-$2.60 - -$2.40-9.31%MissN/A30 up, 0 downAug 11, 2023$217000
    Mar 31, 2023-$0.22-$0.21-$0.23 - -$0.19-4.76%MissN/A20 up, 0 downMay 12, 2023$279000
    Dec 31, 2022-$2.10-$2.00-$2.50 - -$1.00-5.00%MissN/A20 up, 0 downMar 10, 2023$491000
    Sep 30, 2022-$2.50-$2.20-$2.40 - -$2.00-13.64%MissN/A30 up, 0 downNov 14, 2022$265000
    Jun 30, 2022-$2.70-$2.27-$2.60 - -$1.90-18.94%MissN/A30 up, 0 downAug 12, 2022$466000
    Mar 31, 2022-$1.70-$2.25-$2.40 - -$2.10+24.44%BeatN/A20 up, 0 downMay 13, 2022N/A
    Dec 31, 2021-$0.20-$0.25-$0.25 - -$0.25+20.00%BeatN/A20 up, 0 downMar 11, 2022$209000
    Sep 30, 2021-$0.25N/AN/AN/AN/AN/AN/AN/ANov 12, 2021$232000
    Jun 30, 2021-$0.26N/AN/AN/AN/AN/AN/AN/AAug 13, 2021$489000
    Mar 31, 2021-$0.18N/AN/AN/AN/AN/AN/AN/AMay 14, 2021$376000
    Dec 31, 2020-$0.03N/AN/AN/AN/AN/AN/AN/AMar 30, 2021$1.18M
    Sep 30, 2020-$0.66N/AN/AN/AN/AN/AN/AN/ADec 31, 2020$1.86M
    Jun 30, 2020-$0.06N/AN/AN/AN/AN/AN/AN/ASep 30, 2020$876000
    Mar 31, 2020-$0.08N/AN/AN/AN/AN/AN/AN/AJun 29, 2020$1.71M
    Sep 30, 2019-$0.23N/AN/AN/AN/AN/AN/AN/ADec 31, 2019N/A
    Last 28 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$3.26, after -$4.05 the year before. It was -$1.05 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$3.26N/A
    Dec 31, 2024-$4.05N/A
    Dec 31, 2023-$8.22N/A
    Dec 31, 2022-$9.00N/A
    Dec 31, 2021-$0.89N/A
    Dec 31, 2020-$1.05N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 3,500 words across 9 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q2Jun 30, 20263,4619
    2026Q1Mar 31, 20263,6368
    2025Q4Dec 31, 20253,5168
    2025Q3Sep 30, 20256,41210
    2025Q2Jun 30, 20256,97310
    2024Q4Dec 31, 20245,0198
    2024Q3Sep 30, 20244,2328
    2024Q2Jun 30, 20244,5137

    2026Q2 Earnings Call

    Opening remarks

    Derek Cole Investor Relations Advisor Thank you, Rochelle. Good afternoon, everyone, and thank you for joining us today to review Longeveron's second quarter financial results and business update. After the U.S. markets closed today, we issued a press release with financial results for the second quarter which can be found under the Investors section of the Longeveron website. On the call today are Stephen H. Willard, Chief Executive Officer; Dr. Joshua Hare, cofounder, Chief Science Officer, and Executive Chairman of the Board; Dr. Nataliya Agafonova, Chief Medical Officer; Devin Blass, Chief Technology Officer; and Marie Washburn, Chief Financial Officer. As a reminder, during this call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from these statements. Any such statements should be considered in conjunction with cautionary statements in our press releases and risk factors discussed in the company's filings with the Securities and Exchange Commission, which we encourage you to review. Following the company's prepared remarks, we will open the call to questions from covering analysts. With that, let me hand the call over to Stephen H. Willard, Chief Executive Officer. Steve?

    Stephen H. Willard Chief Executive Officer Thank you, Derek, and thank you all for joining us today. This is an incredibly important and exciting time for the company. Longeveron is approaching a series of potentially transformative milestones across our four stem cell therapy development programs that have the potential to redefine the trajectory of our business. As a reminder, we are developing Laromestrocel in four indications with high unmet medical needs: hypoplastic left heart syndrome, Alzheimer's disease, pediatric dilated cardiomyopathy, and aging-related frailty. We have focused our development activities to prioritize our most important near-term catalyst, the data readout from ELPIS II, our Phase 2b clinical trial evaluating Laromestrocel in HLHS. We expect to report that data readout in mid-September. Our approach to stem cell therapy development has garnered external recognition and validation with encouraging data from our clinical trials having been published in Nature Medicine and Cell Stem Cell. Additionally, as you hopefully saw in our announcement yesterday, published clinical trial results which indicate Laromestrocel increases six-minute walk distance in patients with aging-related frailty were the basis for our selection as a finalist for the XPRIZE HealthSpan Competition. XPRIZE HealthSpan is a seven-year, $101 million global competition to revolutionize the way we approach human aging. We are extremely humbled and appreciative to have our stem cell therapy, Laromestrocel, recognized in this manner. We believe that we are the only publicly traded company to receive this honor. XPRIZE team applications were rigorously evaluated for scientific merit and clinical readiness to identify the best, most feasible, and safe approaches to increase human health span.

    Frequently Asked Questions About LGVN

    Did LGVN beat earnings estimates last quarter?

    No. Longeveron LLC reported EPS of -$1.91 for the quarter ended Sep 30, 2026, below the -$1.70 estimate by 12.35%.

    What EPS do analysts expect from LGVN next quarter?

    The consensus EPS estimate for Longeveron LLC for the quarter ending Dec 31, 2026 is -$1.73 from 4 analysts.

    How often does LGVN beat earnings estimates?

    Longeveron LLC beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -8.30%.